Comparing disease activity indices in ulcerative colitis.

BACKGROUND Comparisons between disease activity indices for ulcerative colitis (UC) are few. This study evaluates three indices, to determine the potential impact of inter-observer variation on clinical trial recruitment or outcome as well as their clinical relevance. METHODS One hundred patients with UC were prospectively evaluated, each by four specialists, followed by videosigmoidoscopy, which was later scored by each specialist. The Simple Clinical Colitis Activity (SCCAI), Mayo Clinic and Seo indices were compared by assigning a disease activity category from published thresholds for remission, mild, moderate and severe activity. Inter-observer variation was evaluated using Kappa statistics and its effect for each patient on recruitment and outcome measures for representative clinical trials calculated. Clinical relevance was assessed by comparing an independently assigned clinical category, taking all information into account as if in clinic, with the disease activity assigned by the indices. RESULTS Inter-observer agreement for SCCAI (κ=0.75, 95% CI 0.70-0.81), Mayo Clinic (κ=0.72, 95% CI 0.67-0.78) and Seo (κ=0.89, 95% CI 0.83-0.95) indices was good or very good as was the agreement for rectal bleeding (κ=0.77) and stool frequency (κ=0.90). Endoscopy in the Mayo Clinic index had the greatest variation (κ=0.38). Inter-observer variation alone would have excluded up to 1 in 5 patients from recruitment or remission criteria in representative trials. Categorisation by the SCCAI, Mayo Clinic and Seo indices agreed with the independently assigned clinical category in 61%, 67% and 47% of cases respectively. CONCLUSIONS Trial recruitment and outcome measures are affected by inter-observer variation in UC activity indices, and endoscopic scoring was the component most susceptible to variation.

[1]  D. Altman,et al.  Translational Gastroenterology , 2011 .

[2]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[3]  G. Guyatt,et al.  Assessing disease activity in ulcerative colitis: Patients or their physicians? , 2010, Inflammatory bowel diseases.

[4]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[5]  M. Schwartz,et al.  Is Endoscopy Necessary for the Measurement of Disease Activity in Ulcerative Colitis? , 2005, The American Journal of Gastroenterology.

[6]  J. R. Landis,et al.  An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. , 1977, Biometrics.

[7]  Ami,et al.  Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. , 1989, BMJ.

[8]  J. H. Baron,et al.  Variation Between Observers in Describing Mucosal Appearances in Proctocolitis* , 1964, British medical journal.

[9]  S. Truelove,et al.  Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.

[10]  P. Rutgeerts,et al.  The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.

[11]  C. O'Morain,et al.  Review article: defining remission in ulcerative colitis , 2011, Alimentary pharmacology & therapeutics.

[12]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[13]  J. Lennard-jones,et al.  A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. , 1978, Scandinavian journal of gastroenterology.

[14]  D. Present,et al.  Preliminary report: cyclosporin in treatment of severe active ulcerative colitis , 1990, The Lancet.

[15]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[16]  M. Silverberg,et al.  A systematic prospective comparison of noninvasive disease activity indices in ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[18]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[19]  M. Schwartz,et al.  Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis , 2005, Gut.

[20]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[21]  T. Yao,et al.  An index of disease activity in patients with ulcerative colitis. , 1992, The American journal of gastroenterology.

[22]  P. Rutgeerts,et al.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. , 2003, Gastroenterology.

[23]  J. Reguła,et al.  Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. , 2009, Gastroenterology.

[24]  R. Pounder,et al.  A simple clinical colitis activity index , 1998, Gut.

[25]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .

[26]  D. Altman,et al.  Reliability and initial validation of the ulcerative colitis endoscopic index of severity. , 2013, Gastroenterology.

[27]  S. Vermeire,et al.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. , 2012, Journal of Crohn's & colitis.

[28]  J. Rochon,et al.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.

[29]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[30]  M. Welfare,et al.  Defining Relapse of Ulcerative Colitis Using a Symptom-based Activity Index , 2003, Scandinavian journal of gastroenterology.